ライフサイエンスコーパス: red marrow

1 e to be in the liver and spleen (besides the red marrow).

2 ulate radiation absorbed doses to organs and red marrow.

3 s that delivered identical absorbed doses to red marrow.

4 268 mCi), based on the radiation dose to the red marrow.

5 med maximum tolerated dose of 450 cGy to the red marrow.

6 based on a prescribed radiation dose to the red marrow.

7 y multiples of 24 in the kidneys, 1.8 in the red marrow, 0.65 in the liver, 0.077 in the intestinal w

8 es were as follows: 2.7 mGy, liver; 2.1 mGy, red marrow; 1.7 mGy, testes; and 1.9 mGy, ovaries.

9 Consequently, significantly lower red marrow (2.1 +/- 1.0 cGy/mCi versus 4.3 +/- 1.6 cGy/m

10 rapeutic doses delivering 150-450 cGy to the red marrow (70-296 mCi) and six patients had more than o

11 The contribution to red marrow absorbed dose from beta-emitting radionuclide

12 Calculated red marrow absorbed dose in patients receiving radioimmu

13 of administered activity and whole-body and red marrow-absorbed dose.

14 In this study, we directly estimated red marrow activity concentration and the self-dose comp

15 ere drawn over several lumbar vertebrae, and red marrow activity concentration was quantified.

16 inder of the body is much higher than in the red marrow and a different correction is needed.

17 abeled antibodies, which does not compromise red marrow and may allow, for some patients, a substanti

18 absorbed fraction for total body irradiating red marrow and other skeletal tissues is the inverse of

19 of time-independent proportionality between red marrow and plasma activity concentration may be too

20 The doses to the red marrow and spleen were 0.00797 mGy/MBq (0.0295 rad/m

21 and 0.97 Gy (sacral image-derived method) to red marrow, and 0.57 Gy to total body.

22 Activity concentrations in plasma and red marrow (assuming a plasmacrit of 0.58, an extracellu

23 dose component of absorbed radiation dose to red marrow based on PET/CT of 2 different (124)I-labeled

24 Absorbed doses (whole body and red marrow) based on the simulated (177)Lu-cG250 data co

25 , considering the additional constraint of a red marrow BED less than 1 Gy15, was individually quanti

26 we determined the tumor, liver, spleen, and red marrow biologically effective doses (BEDs) for a max

27 dence times for (11)C-nicotine in the liver, red marrow, brain, and lungs were 0.048 +/- 0.010, 0.031

28 a reverse process of natural replacement of red marrow by yellow marrow.

29 TNF-transgenic mice are caused by yellow to red marrow conversion, with increased myelopoiesis and i

30 were calculated using 2 different methods of red marrow cumulated activity and red marrow-to-blood ac

31 5), whole-body absorbed dose (r = 0.65), and red marrow dose (r = 0.62 and 0.75).

32 and there was a good correlation between the red marrow dose and myelotoxicity.

33 All red marrow dose calculation schemes resulted in essentia

34 The mean red marrow dose estimated for the 90Y-hMN-14 IgG was 1.6

35 e used to accurately scale reference patient red marrow dose estimates and that these dose estimates

36 sulted in < or = grade 2 myelotoxicity and a red marrow dose of 450 cGy resulted in reversible grade

37 Because patients receiving the same red marrow dose often experience different grades of tox

38 The highest correlation observed was between red marrow dose or total body dose and 1/PN (r = 0.86).

39 The tumor-to-red marrow dose ratio was higher for radioimmunotherapy

40 Tumor/red marrow dose ratios exceeded 3:1 for most lesions.

41 umor uptakes (p = 0.02), as well as tumor-to-red marrow dose ratios, than other cancer types.

42 Using an unadjusted red marrow dose to predict toxicity >/= grade 3, there w

43 Red marrow dose, baseline blood counts, multiple bone or

44 ting toxicity among the following variables: red marrow dose, baseline platelet and WBC counts, bone

45 Red marrow dose, baseline platelet or WBC counts and mul

46 However, using a FLT3-L-adjusted red marrow dose, there were 8 true-positives, but only 2

47 Red marrow doses < or = 250 cGy resulted in < or = grade

48 d kidney doses of approximately 0.75 Gy/GBq, red marrow doses of 0.03 Gy/GBq, and salivary gland dose

49 Red marrow doses of up to 350 cGy generally could be del

50 Red marrow doses ranged from 45 to 706 cGy, and whole-bo

51 8 rad/mCi; range, 15.02-37.07 rad/mCi), with red marrow estimates on the order of 3.32 rad/mCi (range

52 uoted for the absorbed dose delivered to the red marrow following marrow-localizing radiolabeled anti

53 Fatty infiltration of haematopoietic red marrow follows irradiation or chemotherapy and is a

54 If patients with diffuse red marrow infiltration and extensive chemotherapeutic p

55 r a range of organs including bone surfaces, red marrow, kidneys, gut, and whole body using scintigra

56 doses (cGy/mCi) delivered to the total body, red marrow, lungs, liver, spleen and kidneys were 0.5 +/

57 The S-value methodology assumes a fixed red marrow mass as defined by the standard Medical Inter

58 oduced in marrow radiation estimates because red marrow mass varies from patient to patient.

59 Single cell suspensions from the red marrow of the long bones were cultured 14 days in vi

60 in the epiphysis, metaphysis, diaphysis, and red marrow of the tibia was obtained.

61 use of this measurement to adjust calculated red marrow or total body radiation doses may provide sig

62 ed doses were calculated for the whole body, red marrow, organs, and tumor metastases for the therape

63 sicles, CB ossicles showed a predominance of red marrow over yellow marrow, as demonstrated by histom

64 toxicity did not correlate with estimates of red marrow radiation absorbed dose, total-body radiation

65 t body weight, total body radiation dose, or red marrow radiation dose and PTG, PPD, PN, and 1/PN.

66 The red marrow radiation doses (cGy) were adjusted for the p

67 FLT3-L-adjusted red marrow radiation doses provide improved correlation

68 Red marrow radiation doses were determined for 30 patien

69 Accurate determination of red marrow radiation is important because myelotoxicity

70 r of recovery of progenitor cells and, thus, red marrow radiosensitivity (because during the recovery

71 h the urinary bladder, osteogenic cells, and red marrow receiving the highest doses at 0.080, 0.077,

72 0.0074 rad/mCi) for the ovaries, testes, and red marrow, respectively.

73 0.04 mGy/MBq delivered to the whole-body and red marrow, respectively.

74 When using the blood-based model of red marrow (RM) absorbed dose estimation, there are only

75 Red marrow (RM) is often the primary organ at risk in ra

76 llows for image-based estimates of organ and red marrow (RM) residence times.

77 Estimates of radiation absorbed dose to the red marrow (RM) would be valuable in treatment planning

78 Plasma-based estimates of red marrow self-dose tended to be greater than image-bas

79 latively increased renal and hepatic uptake, red marrow suppression is the only DLT of 188Re-MN-14.

80 Red marrow suppression was the only DLT observed.

81 Red marrow suppression was the only observed toxicity an

82 The S value assigned to the red marrow target region from activity distributed in th

83 glands, 0.7 Sv for kidneys, and 0.05 Sv for red marrow that are composed of 99.4% alpha, 0.5% beta,

84 rotocol that could show an improved tumor-to-red marrow therapeutic ratio compared with conventional

85 methods of red marrow cumulated activity and red marrow-to-blood activity concentration ratio determi

86 The red marrow-to-plasma activity concentration ratio (RMPR)

87 The average tumor-to-red marrow, tumor-to-liver, tumor-to-lungs, and tumor-to

88 splenic uptake (7.7% +/- 1.0% ad. dose) and red marrow uptake (14 +/- 1.8%) were lower than those of

89 ent of the S value from remainder tissues to red marrow using either MIRD 11 or MIRDOSE3.

90 Thresholds for "normal" red marrow versus pathologic BME were established, and i

91 gan (0.200 mGy/MBq), whereas the dose to the red marrow was 0.006 mGy/MBq.

92 ponent of the absorbed radiation dose to the red marrow was estimated from the images, from the plasm

93 he ranges of absorbed doses delivered to the red marrow were 177-994 and 1-5 mGy/MBq from activity on